drugset / Trial / NCT05832229
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Phase 2
Recruiting
256 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Columbia University · collabDuke University · collabLAC+USC Medical Center · collabMayo Clinic · collabNational Cancer Institute (NCI) · collabNational Institute on Alcohol Abuse and Alcoholism (NIAAA) · collabThe Cleveland Clinic · collabUniversity of California, San Diego · collabUniversity of California, San Francisco · collabUniversity of Miami · collabUniversity of Michigan · collabUniversity of Southern California · collabVirginia Commonwealth University · collabWeill Medical College of Cornell University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a double-blind, phase 2 study to evaluate safety and efficacy of rosuvastatin in comparison to placebo after 2 years in patients with compensated cirrhosis.
Timeline
- Start
- 2023-12-07
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |
| Subject | Rosuvastatin | Small molecule | 20 mg | Oral |